MaxCyte, Inc. (MXCT) News
Follow MaxCyte, Inc. (MXCT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
MaxCyte, Inc. (MXCT) Appoints Chief Corporate Development Officer
MaxCyte appointed Sidharth Kapileshwar as Chief Corporate Development Officer. He previously held leadership roles at Danaher, GE Healthcare, Beckman Coulter, and Halma.Material DetailsContext by AI AnalystThis is an ear
NEWS | Sep 23, 2026, 12:11 PM UTC
L
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. NASDAQ:MXCT, a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of nex
NEWS | Sep 23, 2026, 12:11 PM UTC
L
MXCT - MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
MXCT - MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
NEWS | Sep 23, 2026, 12:05 PM UTC
L
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. NASDAQ:MXCT, a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercializatio
NEWS | Sep 11, 2026, 08:32 PM UTC
L
MXCT - MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MXCT - MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 11, 2026, 08:30 PM UTC
L
MaxCyte launches CHANGE-seq-BE and ONE-seq-BE assays
MaxCyte (NASDAQ: MXCT) announces the launch of CHANGE-seq-BE and ONE-seq-BE off-target nomination assays through its SeQure service for adenine and cytosine base editors.
REGULATION | Aug 19, 2026, 12:07 PM UTC
L
MaxCyte (MXCT) launches CHANGE-seq-BE and ONE-seq-BE off-target tools
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ aimed at strengthening off-target assessment for genome editing therapies.
EQUITY | Aug 19, 2026, 12:05 PM UTC
L
MaxCyte Affirms FY2026 Sales Guidance
MaxCyte affirms FY2026 sales outlook of $30.000M-$32.000M
EARNINGS | Aug 12, 2026, 08:09 PM UTC
L
MXCT Reports Q2 2026 Financial Results
MaxCyte reports second quarter 2026 financial results
EARNINGS | Aug 12, 2026, 08:07 PM UTC
L
MXCT maxcyte® announces multi-platform technology license partnership with genentech® to advance cell therapy development Maxcyte - genentec
MXCT maxcyte® announces multi-platform technology license partnership with genentech® to advance cell therapy development Maxcyte - genentech to access Maxcyte expert gtx platform and technologies for cell therapy workfl
EQUITY | Jul 21, 2026, 12:46 PM UTC